CD274 and renal cell carcinoma: Interestingly, even though immune checkpoint inhibitors have shown high efficacy in advanced renal cell carcinoma, high PD-1 and PD-L1 expressions have been associated with adverse RCC features such as larger renal tumor size or the presence of sarcomatoid features and, consequently, with poor outcomes [116].